Evidence map›Paper›PMID 40754557›Full record

ArticleEJNMMI reports2025

Function of

Clémence M C Huigen, Alexander Coukos, Sofiya Latifyan, Marie Nicod Lalonde, Niklaus Schaefer, Daniel Abler, Adrien Depeursinge, John O Prior, Montserrat Fraga, Mario Jreige

Abstract read
In one paragraph

Article in EJNMMI reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clémence M C HuigenDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0009-0003-2016-3552
Alexander CoukosDepartment of Gastroenterology and Hepatology, Lausanne University Hospital, Lausanne, Switzerland.
Sofiya LatifyanDepartment of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Marie Nicod LalondeDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-4886-0611
Niklaus SchaeferDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-9732-7696
Daniel AblerDepartment of Oncology, Lausanne University Hospital, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-1776-5985
Adrien DepeursingeDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-2362-0304
John O PriorDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Rue du Bugnon 46, 1011, Lausanne, Switzerland. john.prior@chuv.ch.ORCID http://orcid.org/0000-0003-1429-1374
Montserrat FragaDepartment of Gastroenterology and Hepatology, Lausanne University Hospital, Lausanne, Switzerland.
Mario JreigeDepartment of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Rue du Bugnon 46, 1011, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-3918-150X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the last decade, immunotherapy, particularly immune checkpoint inhibitors, has revolutionized cancer treatment and improved prognosis. However, severe checkpoint inhibitor-induced liver injury (CHILI), which can lead to treatment discontinuation or death, occurs in up to 18% of the patients. The aim of this study is to evaluate the value of PET/CT radiomics analysis for the detection of CHILI. MATERIALS AND

methodsPatients with CHILI grade 2 or higher who underwent liver function tests and liver biopsy were retrospectively included. Minors, patients with cognitive impairments, and patients with viral infections were excluded from the study. The patients' liver and spleen were contoured on the anonymized PET/CT imaging data, followed by radiomics feature extraction. Principal component analysis (PCA) and Bonferroni corrections were used for statistical analysis and exploration of radiomics features related to CHILI.

resultsSixteen patients were included and 110 radiomics features were extracted from PET images. Liver PCA-5 showed significance as well as one associated feature but did not remain significant after Bonferroni correction. Spleen PCA-5 differed significantly between CHILI and non-CHILI patients even after Bonferroni correction, possibly linked to the higher metabolic function of the spleen in autoimmune diseases due to the recruitment of immune cells.

conclusionThis pilot study identified statistically significant differences in PET-derived radiomics features of the spleen and observable changes in the liver on PET/CT scans before and after the onset of CHILI. Identifying these features could aid in diagnosing or predicting CHILI, potentially enabling personalized treatment. Larger multicenter prospective studies are needed to confirm these findings and develop automated detection methods.

Indexed as

CHILIHepatic irAEHepatitisImmune checkpoint inhibitorImmune-related adverse eventsRadiomics

Identifiers

PMID40754557
PMCPMC12318889

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.